Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes-Reference-Cited by-同舟云学术

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes

Published:2019-08-07 Issue:1 Volume:21 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Sobral-Leite Marcelo,Salomon Izhar,Opdam Mark,Kruger Dinja T.,Beelen Karin J.,van der Noort Vincent,van Vlierberghe Ronald L. P.,Blok Erik J.,Giardiello Daniele,Sanders Joyce,Van de Vijver Koen,Horlings Hugo M.,Kuppen Peter J. K.,Linn Sabine C.,Schmidt Marjanka K.,Kok Marleen

Funder

Stichting A Sister's Hope

Conselho Nacional de Desenvolvimento Científico e Tecnológico

KWF Kankerbestrijding

Top Institute Pharma

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/s13058-019-1176-2.pdf

Reference48 articles.

1. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.

2. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.